DLL3, expressed in most SCLC patients, is a critical therapeutic target driven by the transcription factor ASCL1, enhancing tumorigenic, clonogenic, and metastatic capacities in preclinical models (27, 53, 108, 129, 130). This evidence concerns the gene DLL3 and small cell lung carcinoma.